Tadalafil FDA Approval: Key U.S. Regulatory Milestones

Tadalafil FDA Approval Timeline

The major FDA milestones show how tadalafil moved from one ED indication to several distinct regulatory product contexts. Importantly, later approvals did not retroactively make every tadalafil brand or generic product part of the original Cialis NDA.

The timeline below separates original NDAs, supplemental indication or regimen changes and first-generic ANDA approvals.

What Does 'Initial U.S. Approval: 2003' Mean for Tadalafil?

Current tadalafil labeling commonly identifies 2003 as the initial U.S. approval year because that is when the active drug first entered the U.S. market through Cialis. It does not mean every later tadalafil product, indication, dosage form or regimen was approved in 2003.

This distinction is especially important with Adcirca. Its current label can state an initial U.S. tadalafil approval of 2003 while the PAH-specific Adcirca marketing approval itself occurred in 2009 under a different NDA.

The Cialis NDA Entered FDA Review in 2001

FDA records for NDA 21-368 identify the original Cialis application as dated June 28, 2001 and received by the agency on June 29, 2001. Submission of an NDA begins regulatory review but is not itself the same event as marketing approval.

The review continued through additional submissions and safety questions before the 2003 action that established Cialis as an approved U.S. ED treatment. This illustrates why filing dates and approval dates should not be used interchangeably.

The Original Cialis Approval Was for Erectile Dysfunction

FDA records show an action date of November 21, 2003 for NDA 21-368, establishing Cialis as a U.S. treatment for erectile dysfunction. The original indication should be kept separate from later BPH and combined ED/BPH approvals.

This means a historical statement that Cialis was 'FDA approved in 2003' is correct, but saying it was approved in 2003 for every indication appearing in today's label would be inaccurate.

The current ED treatment context is covered on Tadalafil for Erectile Dysfunction.

Cialis Label Evolution Happened Through Later FDA Actions

An approved drug can acquire new indications, regimens or labeling through supplemental new drug applications after the original NDA approval. Tadalafil is a clear example: the U.S. Cialis framework evolved after 2003 instead of remaining limited to its original as-needed ED context.

The major efficacy-related additions were once-daily ED treatment in 2008 and BPH plus combined ED/BPH treatment in 2011. These later actions are regulatory extensions of NDA 21-368 rather than separate discoveries of a new active ingredient.

Once-Daily ED Treatment Was Added in January 2008

FDA's later review history for NDA 21-368 states that a new once-daily ED regimen was approved in January 2008. The regimen consisted of a single daily 2.5 mg or 5 mg tadalafil tablet rather than the original event-linked as-needed structure.

Regulatory approval of daily treatment did not replace as-needed tadalafil. It created a second labeled ED framework under the same Cialis NDA, which is why modern ED labeling contains both treatment patterns.

Their clinical differences are explained on Daily vs As-Needed Tadalafil.

The PAH Regulatory Path Began Before Adcirca Approval

FDA's orphan-drug database records a December 18, 2006 orphan designation for tadalafil for treatment of pulmonary arterial hypertension. Orphan designation and marketing approval are separate regulatory events: designation can support development of a drug for a qualifying rare disease but does not itself authorize marketing.

The eventual Adcirca approval followed in 2009 after FDA reviewed the PAH-specific efficacy and safety application.

Adcirca Created a Separate FDA-Approved Tadalafil PAH Context in 2009

FDA approved Adcirca on May 22, 2009 under NDA 22-332 for pulmonary arterial hypertension, WHO Group 1, to improve exercise ability. The application was a separate NDA from Cialis, even though both products rely on tadalafil as the active ingredient.

FDA review documents describe Adcirca as tadalafil 20 mg tablets and the PAH treatment framework as 40 mg once daily. This regulatory separation is why Cialis instructions should not simply be copied onto Adcirca or vice versa.

The disease-specific context belongs on Tadalafil for Pulmonary Hypertension and the identity relationship on Tadalafil and Adcirca.

FDA Added BPH to the Cialis Label in October 2011

NDA 21-368 Supplement 20 sought approval of Cialis for treatment of the signs and symptoms of benign prostatic hyperplasia. FDA review materials identify October 6, 2011 as the action/PDUFA date, and the updated labeling introduced BPH as a Cialis indication.

This was a true indication expansion rather than merely a clarification of the original ED label. Current Cialis labeling continues to list treatment of the signs and symptoms of BPH as a distinct indication.

The clinical role is covered on Tadalafil for BPH.

A Separate Combined ED/BPH Indication Was Added at the Same Time

Supplement 21 addressed men who had both erectile dysfunction and signs and symptoms of BPH. FDA review materials evaluated this as a separate indication from BPH alone, and the October 2011 label expansion added the combined ED/BPH context.

This regulatory structure matters because the modern label does not merely mention ED and BPH separately. It explicitly recognizes their coexistence as another labeled treatment framework.

That use is explained on Tadalafil for ED and BPH.

What Indications Remain in the Current U.S. Cialis Label?

The current U.S. Cialis label continues to identify three indication lines: erectile dysfunction, the signs and symptoms of BPH, and ED together with the signs and symptoms of BPH. The current label therefore reflects multiple regulatory stages accumulated since the original 2003 approval.

PAH is not part of the current Cialis indication list. That condition belongs to separately approved tadalafil product contexts such as Adcirca and Tadliq.

NDA and Supplemental NDA Are Different Regulatory Events

The original NDA is the application through which a new drug product enters FDA review for marketing approval. After approval, sponsors can submit supplemental applications to obtain approval for important changes such as new indications or dosing frameworks.

Tadalafil illustrates both mechanisms: NDA 21-368 established Cialis, while later supplements expanded how that approved product could be used. Adcirca, by contrast, entered the PAH context under its own NDA 22-332.

Generic Tadalafil Entered Through ANDAs, Not New Cialis NDAs

Generic drugs generally enter the U.S. regulatory system through abbreviated new drug applications, or ANDAs, referencing an approved drug product. An ANDA pathway relies on requirements such as pharmaceutical equivalence and bioequivalence rather than repeating the reference product's original full efficacy-development program.

This is why generic tadalafil approval dates are different regulatory milestones from the original Cialis or Adcirca NDA dates. Generic approval means FDA authorized that specific generic application; it does not rewrite when tadalafil itself was first approved.

The generic relationship is covered on Generic Tadalafil.

The First FDA-Listed Generic Referencing Cialis Was Approved in May 2018

FDA's 2018 first-generic records list Teva Pharmaceutical USA's tadalafil tablets under ANDA 090141 as approved on May 22, 2018. The entry references Cialis and lists 2.5 mg, 5 mg, 10 mg and 20 mg tablet strengths.

FDA's first-generic entry identifies the indications in the Cialis-type context as ED, BPH and combined ED/BPH. The approval date should not automatically be interpreted as the date a particular generic became available at every pharmacy, because FDA notes that approval and commercial availability are not always simultaneous.

A Separate First Generic Referencing Adcirca Followed in August 2018

FDA's first-generic records separately list Mylan Pharmaceuticals' tadalafil 20 mg tablets under ANDA 200630, approved on August 3, 2018 with Adcirca as the reference product. This demonstrates that generic tadalafil evolved through more than one reference-product pathway.

The Adcirca-referencing generic belongs to the PAH tablet context, not to the Cialis ED/BPH pathway simply because the active ingredient is also tadalafil.

The 2018 Generic Milestones Show Why 'Generic Tadalafil' Needs Product Context

The two 2018 first-generic records illustrate a broader regulatory principle: the active ingredient name alone does not identify the reference product. One tadalafil ANDA can reference Cialis in the ED/BPH context while another references Adcirca in the PAH context.

Accordingly, 'FDA-approved generic tadalafil' should not automatically be interpreted as one universal tablet carrying every possible tadalafil indication. Reference product, strength, dosage form and approved labeling remain relevant.

Tadliq Added a New FDA-Approved Tadalafil Dosage Form in 2022

FDA approved Tadliq under NDA 214522 on June 17, 2022. The product contains tadalafil as an oral suspension and is indicated for pulmonary arterial hypertension, WHO Group 1, to improve exercise ability.

Tadliq is historically important because its approval expanded the U.S. tadalafil product landscape beyond tablets. It was a separate NDA approval, not an ANDA generic approval and not a supplemental approval to Cialis.

The dosage form is explained on Tadalafil Oral Suspension and the product on Tadliq.

An Approval Date Is Not the Same as a Later Label-Update Date

Drug labels continue to change after initial approval as safety information, indications, instructions or administrative information are updated. A current label's revision date therefore should not be mistaken for the date on which the product or indication first received FDA approval.

For example, the current Cialis label may be updated years after 2003 while still identifying 2003 as the initial U.S. approval. The regulatory timeline must rely on the relevant approval action rather than treating the newest label revision as a new drug approval.

One Molecule Can Have Multiple FDA Approval Contexts

Tadalafil demonstrates why it can be misleading to ask for 'the FDA approval date' without specifying what is being dated. The molecule first entered the U.S. market through Cialis in 2003, but PAH, BPH, combined ED/BPH, generics and an oral suspension each have later regulatory milestones.

The correct answer therefore depends on whether the question concerns the molecule's first U.S. approval, a particular indication, a specific brand, a dosing framework or an individual generic application.

FDA Approval Does Not Make Every Tadalafil Product Interchangeable

FDA approval establishes a specific product and labeling context. Sharing tadalafil as the active ingredient does not mean Cialis, Adcirca, Tadliq and every generic tadalafil product can be substituted for one another without regard to indication, dosage form, strength or reference product.

This distinction is especially important because tadalafil spans both ED/BPH and PAH regulatory branches. Product identity should therefore be read alongside FDA approval status rather than inferred from the molecule name alone.

FDA Approval Does Not Mean a Drug Is Appropriate for Every Patient

An FDA-approved indication means the agency has reviewed the evidence supporting use under the approved conditions; it does not mean tadalafil is appropriate for every person with that diagnosis. Contraindications, interactions, organ function and other patient-specific considerations remain part of prescribing.

This distinction is regulatory as well as clinical: approval defines an authorized product context, while individual suitability remains a separate question. Safety detail belongs on Tadalafil Contraindications and Tadalafil Drug Interactions.

FDA Approval History Is Narrower Than Tadalafil's Full History

The FDA timeline begins with U.S. regulatory submissions and actions. Tadalafil's broader history also includes preclinical development, ICOS, Lilly ICOS, European authorization, corporate ownership changes and commercial evolution, none of which should dominate a page centered on FDA approvals.

Those events are intentionally kept on Tadalafil History. This page instead treats application numbers, indications, supplemental approvals and generic pathways as the organizing framework.

Common Misunderstandings About Tadalafil FDA Approval

The phrase 'tadalafil FDA approval' can hide several different regulatory questions. The most common errors are assuming that every current indication was approved in 2003, treating Adcirca as part of the original Cialis NDA, or describing the first generic approval as though FDA had only then approved tadalafil itself.

A more accurate regulatory model separates original NDA approval, supplemental label expansion, separate product NDAs and ANDA generic approvals.

Explore Tadalafil's Regulatory and Product Context

The U.S. regulatory timeline connects the original Cialis NDA, later indication expansions, the Adcirca PAH branch, generic competition and a newer oral-suspension product. Related pages provide the clinical, historical and product identity details that do not belong in a regulatory chronology.

Keeping those intents separate allows this page to remain focused on what FDA approved, when it did so and which application or product context was involved.